Vivani Medical (NASDAQ:VANI) Shares Down 0.9% – Here’s What Happened

Posted by Stanley Muller on Jun 11th, 2026

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report)’s share price was down 0.9% during trading on Tuesday . The company traded as low as $1.13 and last traded at $1.14. Approximately 145,122 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 192,362 shares. The stock had previously closed at $1.15.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VANI shares. HC Wainwright decreased their target price on Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a report on Tuesday. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.50.

Check Out Our Latest Stock Report on Vivani Medical

Vivani Medical Stock Performance

The stock has a fifty day moving average of $1.21 and a 200 day moving average of $1.26. The company has a market capitalization of $97.45 million, a P/E ratio of -2.82 and a beta of 2.31.

Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Research analysts anticipate that Vivani Medical, Inc. will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling

In other Vivani Medical news, Director Gregg Williams purchased 1,587,301 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the acquisition, the director directly owned 34,531,785 shares in the company, valued at $43,510,049.10. The trade was a 4.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 4,749,833 shares of company stock worth $5,685,496 over the last quarter. 53.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VANI. Tudor Investment Corp ET AL purchased a new position in shares of Vivani Medical during the fourth quarter valued at about $1,127,000. Marshall Wace LLP purchased a new position in shares of Vivani Medical during the fourth quarter valued at about $174,000. Geode Capital Management LLC grew its position in shares of Vivani Medical by 29.6% during the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after purchasing an additional 105,398 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Vivani Medical during the fourth quarter valued at about $60,000. Hedge funds and other institutional investors own 6.78% of the company’s stock.

About Vivani Medical

(Get Free Report)

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.